This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of Pittsburgh, National Research Council of Canada. Active years: 2021-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 1,960 
2 out of 1,039 Years Active: 2021-2026
Title: Andrew Peterson Hinck: Innovator in TGF-beta Research
Introduction
Andrew Peterson Hinck is a notable inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of biomedical research, particularly in the area of transforming growth factor (TGF)-beta signaling. With a total of 3 patents, his work has the potential to impact various medical treatments.
Latest Patents
Hinck's latest patents focus on engineered TGF-beta monomers and their applications for inhibiting TGF-beta signaling. These recombinant TGF-beta monomers are modified to prevent dimerization and block TGF-beta signaling pathways. Notably, these monomers do not bind to the TGF-beta type I receptor but can still interact with the high-affinity TGF-beta type II receptor. Some variants even include mutations that enhance their binding affinity for TGF-beta type II receptor. Additionally, the patents describe nucleic acid molecules and vectors that encode these recombinant TGF-beta monomers. Isolated cells, such as T cells, can be reprogrammed to secrete these monomers, which can be utilized to inhibit TGF-beta signaling and potentially treat disorders linked to abnormal TGF-beta activity.
Career Highlights
Hinck has worked with prestigious institutions, including the University of Pittsburgh and the National Research Council of Canada. His research has been pivotal in advancing our understanding of TGF-beta signaling and its implications in various diseases.
Collaborations
Hinck has collaborated with Traian Sulea, contributing to the innovative research in the field of TGF-beta signaling.
Conclusion
Andrew Peterson Hinck's work in engineered TGF-beta monomers represents a significant advancement in biomedical research. His contributions have the potential to lead to new therapeutic strategies for treating disorders associated with TGF-beta signaling.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile